The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 16 April 2026•Updated 17 April 2026•

1 min read

WuXi Biologics Achieves ISO 13485 Certification for Medical Device Quality Management

Key Facts

1WuXi Biologics achieved ISO 13485:2016 Medical Device Quality Management System certification with zero non-conformities.

about 2 months ago

Version History

Version 1about 2 months ago

What changed: The story was updated to include the company being named an ESG Industry and Regional Leader by Morningstar Sustainalytics for the sixth consecutive year.

WuXi Biologics (2269.HK) has achieved the ISO 13485:2016 certification for Medical Device Quality Management Systems with zero non-conformities, solidifying its position in China's drug-device combination sector. In addition to this technical milestone, the company has been named an Industry and Regional ESG Leader for 2026 by Morningstar Sustainalytics. This recognition marks the sixth consecutive year that WuXi Biologics has received this prestigious honor, highlighting its sustained commitment to environmental, social, and governance excellence. These dual achievements enhance the company's competitive edge and are expected to attract broader global contracts by ensuring regulatory compliance and ethical standards. Analysts view these developments as significant drivers for long-term international expansion and operational credibility. The company continues to demonstrate leadership in providing integrated solutions within the high-growth biotechnology market.